After lengthy delay, GSK to release vax data; Anthrax vax makers see shares drop;

Vaccine Research

After waiting for more than a year, GlaxoSmithKline says it is now ready to release data on a head-to-head clinical study comparing its cervical cancer vaccine against Merck's. And one expert says that the lengthy wait has raised both his eyebrows. Report

The New Scientist magazine reports on the progress of a team of Harvard researchers studying a new universal flu vaccine. Story

An experimental ebola vaccine has demonstrated its safety in STAT-1 knockout-mice and evaluated its protective efficacy in mice and guinea pigs. Release

A Phase IIb proof-of-concept clinical trial of a promising new TB vaccine developed at the University of Oxford--called MVA85A/AERAS-485--has been launched. Release

Vical announced the publication of data from preclinical studies identifying potential targets for development of a herpes simplex virus type 2 vaccine. Release

The first-proof-of-concept for a DNA-based therapeutic vaccination against chronic hepatitis C was announced today at EASL 2009, the Annual Meeting of the European Association for the Study of the Liver in Copenhagen, Denmark. Release

Vaccine Market

Shares of several vaccine makers were dragged down earlier in the week after the government asked the bidders on a new anthrax vaccine contract to submit a comprehensive regulatory plan in 15 days. Report

Wyeth is donating three million doses of Prevnar to two African counties in the first national immunization programs aimed at pneumococcal disease in a developing nation. Story

A meningitis epidemic is sweeping West Africa at a time when global supplies of meningitis vaccine are low. Story

A sixth case of measles has been reported in the Washington area. Report

Suggested Articles

The pandemic price could be lowered for larger deals, CEO Stephane Bancel said. Pfizer and BioNTech priced 100M doses at $19.50 each for the U.S.

Pfizer and BioNTech followed supply pacts in the U.S. and U.K. with a new deal to deliver 120 million vaccines to Japan in the first half of 2021.

Sanofi's cost cuts are adding up, execs said in an update Wednesday. The company has trimmed nearly €1 billion in annual expenses so far in 2020.